Depressing Clinical Trial News

Smoke 'em if you got 'em, boys -- this drug is finished.

AstraZeneca (NYSE: AZN  ) and Targacept (Nasdaq: TRGT  ) , which was spun out of Reynolds America, said today that two more phase 3 trials of their depression drug TC-5214 failed, so the companies won't attempt to gain FDA approval for the drug.

TC-5214, which affects the same neuronal receptor as nicotine, failed to show a substantial increase in the standard measurement for depression -- the Montgomery-Asberg Depression Rating Scale -- compared to placebo. In reality, it might be the placebo that was the problem; like in the two trials that failed last year, patients getting placebo saw at least a 40% increase in their MADRS score. It's difficult to see an effect with that much background noise.

The companies were testing TC-5214 in combination with another depression drug -- Eli Lilly's (NYSE: LLY  ) Cymbalta or Pfizer's (NYSE: PFE  ) Zoloft, for instance-- that wasn't giving adequate improvement. The add-on strategy is how Bristol-Myers Squibb (NYSE: BMY  ) got its antipsychotic, Abilify, into the depression market, and this is the easiest strategy at this point. With so many generics available, it's easier to join 'em than even try to beat 'em.

AstraZeneca and Targacept are separately testing TC-5214 as a monotherapy to see if it can help patients that didn't respond to other therapies. That phase 2b trial could have the same placebo-effect issues, but at least that trial has an active comparator, Cymbalta, so it'll be easier to see exactly what's going on.

Investors are valuing Targacept at less than its cash on hand, which might be shortsighted. Sure, the valuation is reasonable if TC-5214 is dead and Targacept has to develop the rest of the pipeline on its own -- the biotech will burn through much, maybe all, of its $225 million developing its phase 2 schizophrenia drug and the rest of its pipeline. But the drugs might have value to some other drugmaker, and Targacept plans to announce by the end next month its plan -- a sale, perhaps -- given the TC-5214 phase 3 failure. While today's news was depressing, investors' MADRS score will go through the roof if Targacept is sold.

David Gardner and his team at Rule Breakers aren't counting on an acquisition to get solid returns from one of their recent healthcare picks. Find out what it is and why they like it in the Fool's free report, "Discover the Next Rule-Breaking Multibagger."

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1831440, ~/Articles/ArticleHandler.aspx, 9/16/2014 1:52:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,166.37 135.23 0.79%
S&P 500 2,001.70 17.57 0.89%
NASD 4,553.47 34.57 0.77%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/16/2014 1:36 PM
AZN $73.70 Down -0.08 -0.11%
AstraZeneca plc (A… CAPS Rating: ***
TRGT $2.50 Down -0.02 -0.79%
Targacept , Inc. CAPS Rating: ***
BMY $50.86 Up +0.91 +1.82%
Bristol-Myers Squi… CAPS Rating: ****
LLY $65.89 Up +0.70 +1.07%
Eli Lilly & Co. CAPS Rating: ****
PFE $30.06 Up +0.14 +0.45%
Pfizer CAPS Rating: ****

Advertisement